AstraZeneca (AZN) Rating Reiterated by Barclays

Barclays reiterated their overweight rating on shares of AstraZeneca (LON:AZN) in a research note published on Tuesday, February 5th.

A number of other research firms have also recently weighed in on AZN. HSBC set a GBX 4,860 ($63.50) target price on shares of AstraZeneca and gave the stock a sell rating in a research note on Monday, November 12th. Goldman Sachs Group set a GBX 4,080 ($53.31) target price on shares of AstraZeneca and gave the stock a sell rating in a research note on Friday, November 16th. JPMorgan Chase & Co. set a GBX 6,900 ($90.16) target price on shares of AstraZeneca and gave the stock a buy rating in a research note on Friday, November 16th. Kepler Capital Markets reaffirmed a buy rating and set a GBX 6,100 ($79.71) target price on shares of AstraZeneca in a research note on Thursday, November 22nd. Finally, Investec cut shares of AstraZeneca to a hold rating and boosted their target price for the stock from GBX 5,500 ($71.87) to GBX 6,300 ($82.32) in a research note on Monday, November 19th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have issued a buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of GBX 6,236.20 ($81.49).

LON:AZN traded up GBX 47 ($0.61) during mid-day trading on Tuesday, reaching GBX 6,186 ($80.83). The stock had a trading volume of 2,191,759 shares, compared to its average volume of 2,310,000. AstraZeneca has a 12 month low of GBX 4,260 ($55.66) and a 12 month high of GBX 5,520 ($72.13).

The business also recently disclosed a dividend, which will be paid on Wednesday, March 27th. Stockholders of record on Thursday, February 28th will be issued a dividend of GBX 146.80 ($1.92) per share. The ex-dividend date is Thursday, February 28th. This represents a dividend yield of 2.57%. This is a positive change from AstraZeneca’s previous dividend of $68.40.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Article: Average Daily Trade Volume – What You Need to Know

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.